Moleculin Z Score

MBRX -  USA Stock  

USD 1.46  0.07  5.04%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Additionally, see Moleculin Biotech Piotroski F Score and Moleculin Biotech Valuation analysis.
  
Refresh
Moleculin Biotech Return on Invested Capital is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Return on Invested Capital of 12.21 in 2021. Working Capital is likely to rise to about 74.3 M in 2022, whereas Capital Expenditure is likely to drop (20.5 K) in 2022. Moleculin Biotech Interest Expense is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Interest Expense of 38,700 in 2021. Weighted Average Shares is likely to rise to about 29 M in 2022, whereas Consolidated Income is likely to drop (16.3 M) in 2022.

Moleculin Z Score Analysis

Moleculin Biotech's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2019 2020 2021 2022 (projected)
Current Assets13.48 M17.2 M72.5 M78.22 M
Total Assets25.23 M29.03 M84.09 M90.73 M
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

Moleculin Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

Based on the company's disclosures, Moleculin Biotech CS has a Z Score of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The z score for all United States stocks is 100.0% higher than that of the company.

Moleculin Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moleculin Biotech from analyzing Moleculin Biotech's financial statements. These drivers represent accounts that assess Moleculin Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moleculin Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Average Assets20.42 M22.37 M27.2 M28.26 M91.53 M98.75 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings before Tax(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Average Equity17.8 M16.64 M17.83 M15.79 M83.37 M89.95 M
Enterprise Value30.58 M19.61 M26.74 M37.19 M(21.95 M)(22.53 M)
Free Cash Flow(7.35 M)(12.62 M)(17.25 M)(18.14 M)(18.97 M)(19.47 M)
Invested Capital(1.59 M)(2.58 M)58 K(51 K)(1.52 M)(1.56 M)
Invested Capital Average(1.37 M)(2.15 M)(4.8 M)(107.75 K)(1.3 M)(1.41 M)
Market Capitalization39.31 M28.21 M41.85 M49.79 M53.15 M51.11 M
Tangible Asset Value8.34 M8.44 M14.09 M17.88 M72.94 M78.7 M
Working Capital6.09 M4.1 M9.91 M14.28 M68.88 M74.31 M

Moleculin Fundamentals

About Moleculin Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech CS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech CS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Current Sentiment - MBRX

Moleculin Biotech Investor Sentiment

Most of Macroaxis users are now bullish on Moleculin Biotech CS. What is your trading attitude regarding investing in Moleculin Biotech CS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moleculin Biotech Piotroski F Score and Moleculin Biotech Valuation analysis. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.7 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.